GIPC1 and DAB2IP, which regulate PI3K–AKT, ERK, and RhoA pathways, are predominantly reduced in dedifferentiated tumor subtypes, consistent with the release of growth-promoting signaling. Here, DAB2IP is linked to neoplasm.